Serum Zonulin Measured by Commercial Kit Fails to Correlate With Physiologic Measures of Altered Gut Permeability in First Degree Relatives of Crohn's Disease Patients

The CCC GEM Project Research Consortium

doi:10.3389/fphys.2021.645303

Serum Zonulin Measured by Commercial Kit Fails to Correlate With Physiologic Measures of Altered Gut Permeability in First Degree Relatives of Crohn's Disease Patients

The CCC GEM Project Research Consortium

Medicine

Résultat de recherche: Article › examen par les pairs

19 Citations (Scopus)

Résumé

Intestinal epithelial cell tight junctions (TJs) contribute to the integrity of the intestinal barrier allowing for control of the physical barrier between external antigens or bacterial products and the internal environment. Zonula occludens-1 (ZO-1) is a protein that modulates intestinal TJs, and serum levels of ZO-1 has been suggested as a biomarker of disrupted barrier function in humans. Previous studies suggested that increased intestinal permeability was associated with evidence of TJ abnormalities. However, there is limited information on the serological measurement of ZO-1 and its relation to other tests of barrier function in healthy subjects. We investigated the correlation of serum ZO-1, with physiologic measures of intestinal permeability (as the ratio of the fractional excretion of lactulose-mannitol or LMR) in a cohort of 39 healthy FDRs of Crohn's disease (CD) patients. No significant correlation was found between LMR and ZO-1 levels (r2 = 0.004, P < 0.71), or intestinal fatty acid binding proteins (I-FABP) (r2 = 0.004, P < 0.71). In conclusion, our data show that ZO-1 and I-FABP are not a marker of gut permeability as defined by LMR.

Langue d'origine	English
Numéro d'article	645303
Journal	Frontiers in Physiology
Volume	12
DOI	https://doi.org/10.3389/fphys.2021.645303
Statut de publication	Published - mars 25 2021

Note bibliographique

Funding Information:
We thank Kevin Ow, Ashleigh Goethel, Heather MacAulay, and everyone in the members of the CCC GEM Global Project Office. Funding. This study was supported by grants from Crohn's and Colitis Canada (Grant No. CCC-GEMIII), Canadian Institutes of Health Research (CIHR) (Grant No. CMF108031), and the Helmsley Charitable Trust. KC was partially supported by a Canada Research Chair in Inflammatory Bowel Diseases. WT was a former recipient of a Post-doctoral Fellowship Research Award from the CIHR Fellowship/Canadian Association of Gastroenterology/Ferring Pharmaceuticals Inc. and a recipient of a fellowship from the Department of Medicine, Mount Sinai Hospital, Toronto, Canada.

Funding Information:
This study was supported by grants from Crohn’s and Colitis Canada (Grant No. CCC-GEMIII), Canadian Institutes of Health Research (CIHR) (Grant No. CMF108031), and the Helmsley Charitable Trust. KC was partially supported by a Canada Research Chair in Inflammatory Bowel Diseases. WT was a former recipient of a Postdoctoral Fellowship Research Award from the CIHR Fellowship/Canadian Association of Gastroenterology/Ferring Pharmaceuticals Inc. and a recipient of a fellowship from the Department of Medicine, Mount Sinai Hospital, Toronto, Canada.

Publisher Copyright:
© Copyright © 2021 Power, Turpin, Espin-Garcia, Smith, The CCC GEM Project Research Consortium and Croitoru.

ASJC Scopus Subject Areas

Physiology
Physiology (medical)

PubMed: MeSH publication types

Journal Article

Accès au document

10.3389/fphys.2021.645303

Autres fichiers et liens

Citer

@article{23b6867b10d7445f96f891e019c9c394,

title = "Serum Zonulin Measured by Commercial Kit Fails to Correlate With Physiologic Measures of Altered Gut Permeability in First Degree Relatives of Crohn's Disease Patients",

abstract = "Intestinal epithelial cell tight junctions (TJs) contribute to the integrity of the intestinal barrier allowing for control of the physical barrier between external antigens or bacterial products and the internal environment. Zonula occludens-1 (ZO-1) is a protein that modulates intestinal TJs, and serum levels of ZO-1 has been suggested as a biomarker of disrupted barrier function in humans. Previous studies suggested that increased intestinal permeability was associated with evidence of TJ abnormalities. However, there is limited information on the serological measurement of ZO-1 and its relation to other tests of barrier function in healthy subjects. We investigated the correlation of serum ZO-1, with physiologic measures of intestinal permeability (as the ratio of the fractional excretion of lactulose-mannitol or LMR) in a cohort of 39 healthy FDRs of Crohn's disease (CD) patients. No significant correlation was found between LMR and ZO-1 levels (r2 = 0.004, P < 0.71), or intestinal fatty acid binding proteins (I-FABP) (r2 = 0.004, P < 0.71). In conclusion, our data show that ZO-1 and I-FABP are not a marker of gut permeability as defined by LMR.",

author = "{The CCC GEM Project Research Consortium} and Namita Power and Williams Turpin and Osvaldo Espin-Garcia and Smith, {Michelle I.} and Kenneth Croitoru and Maria Abreu and Paul Beck and Charles Bernstein and Leo Dieleman and Brian Feagan and Anne Griffiths and David Guttman and Kevan Jacobson and Gilaad Kaplan and Krause, {Denis O.} and Karen Madsen and John Marshall and Paul Moayyedi and Mark Ropeleski and Ernest Seidman and Mark Silverberg and Scott Snapper and Andy Stadnyk and Hillary Steinhart and Michael Surette and Dan Turner and Thomas Walters and Bruce Vallance and Guy Aumais and Alain Bitton and Maria Cino and Jeff Critch and Lee Denson and Colette Deslandres and Wael El-Matary and Hans Herfarth and Peter Higgins and Hien Huynh and Jeff Hyams and David Mack and Jerry McGrath and Anthony Otley and Remo Panancionne",

note = "Funding Information: We thank Kevin Ow, Ashleigh Goethel, Heather MacAulay, and everyone in the members of the CCC GEM Global Project Office. Funding. This study was supported by grants from Crohn's and Colitis Canada (Grant No. CCC-GEMIII), Canadian Institutes of Health Research (CIHR) (Grant No. CMF108031), and the Helmsley Charitable Trust. KC was partially supported by a Canada Research Chair in Inflammatory Bowel Diseases. WT was a former recipient of a Post-doctoral Fellowship Research Award from the CIHR Fellowship/Canadian Association of Gastroenterology/Ferring Pharmaceuticals Inc. and a recipient of a fellowship from the Department of Medicine, Mount Sinai Hospital, Toronto, Canada. Funding Information: This study was supported by grants from Crohn{\textquoteright}s and Colitis Canada (Grant No. CCC-GEMIII), Canadian Institutes of Health Research (CIHR) (Grant No. CMF108031), and the Helmsley Charitable Trust. KC was partially supported by a Canada Research Chair in Inflammatory Bowel Diseases. WT was a former recipient of a Postdoctoral Fellowship Research Award from the CIHR Fellowship/Canadian Association of Gastroenterology/Ferring Pharmaceuticals Inc. and a recipient of a fellowship from the Department of Medicine, Mount Sinai Hospital, Toronto, Canada. Publisher Copyright: {\textcopyright} Copyright {\textcopyright} 2021 Power, Turpin, Espin-Garcia, Smith, The CCC GEM Project Research Consortium and Croitoru.",

year = "2021",

month = mar,

day = "25",

doi = "10.3389/fphys.2021.645303",

language = "English",

volume = "12",

journal = "Frontiers in Physiology",

issn = "1664-042X",

publisher = "Frontiers Research Foundation",

}

TY - JOUR

T1 - Serum Zonulin Measured by Commercial Kit Fails to Correlate With Physiologic Measures of Altered Gut Permeability in First Degree Relatives of Crohn's Disease Patients

AU - The CCC GEM Project Research Consortium

AU - Power, Namita

AU - Turpin, Williams

AU - Espin-Garcia, Osvaldo

AU - Smith, Michelle I.

AU - Croitoru, Kenneth

AU - Abreu, Maria

AU - Beck, Paul

AU - Bernstein, Charles

AU - Dieleman, Leo

AU - Feagan, Brian

AU - Griffiths, Anne

AU - Guttman, David

AU - Jacobson, Kevan

AU - Kaplan, Gilaad

AU - Krause, Denis O.

AU - Madsen, Karen

AU - Marshall, John

AU - Moayyedi, Paul

AU - Ropeleski, Mark

AU - Seidman, Ernest

AU - Silverberg, Mark

AU - Snapper, Scott

AU - Stadnyk, Andy

AU - Steinhart, Hillary

AU - Surette, Michael

AU - Turner, Dan

AU - Walters, Thomas

AU - Vallance, Bruce

AU - Aumais, Guy

AU - Bitton, Alain

AU - Cino, Maria

AU - Critch, Jeff

AU - Denson, Lee

AU - Deslandres, Colette

AU - El-Matary, Wael

AU - Herfarth, Hans

AU - Higgins, Peter

AU - Huynh, Hien

AU - Hyams, Jeff

AU - Mack, David

AU - McGrath, Jerry

AU - Otley, Anthony

AU - Panancionne, Remo

N1 - Funding Information: We thank Kevin Ow, Ashleigh Goethel, Heather MacAulay, and everyone in the members of the CCC GEM Global Project Office. Funding. This study was supported by grants from Crohn's and Colitis Canada (Grant No. CCC-GEMIII), Canadian Institutes of Health Research (CIHR) (Grant No. CMF108031), and the Helmsley Charitable Trust. KC was partially supported by a Canada Research Chair in Inflammatory Bowel Diseases. WT was a former recipient of a Post-doctoral Fellowship Research Award from the CIHR Fellowship/Canadian Association of Gastroenterology/Ferring Pharmaceuticals Inc. and a recipient of a fellowship from the Department of Medicine, Mount Sinai Hospital, Toronto, Canada. Funding Information: This study was supported by grants from Crohn’s and Colitis Canada (Grant No. CCC-GEMIII), Canadian Institutes of Health Research (CIHR) (Grant No. CMF108031), and the Helmsley Charitable Trust. KC was partially supported by a Canada Research Chair in Inflammatory Bowel Diseases. WT was a former recipient of a Postdoctoral Fellowship Research Award from the CIHR Fellowship/Canadian Association of Gastroenterology/Ferring Pharmaceuticals Inc. and a recipient of a fellowship from the Department of Medicine, Mount Sinai Hospital, Toronto, Canada. Publisher Copyright: © Copyright © 2021 Power, Turpin, Espin-Garcia, Smith, The CCC GEM Project Research Consortium and Croitoru.

PY - 2021/3/25

Y1 - 2021/3/25

N2 - Intestinal epithelial cell tight junctions (TJs) contribute to the integrity of the intestinal barrier allowing for control of the physical barrier between external antigens or bacterial products and the internal environment. Zonula occludens-1 (ZO-1) is a protein that modulates intestinal TJs, and serum levels of ZO-1 has been suggested as a biomarker of disrupted barrier function in humans. Previous studies suggested that increased intestinal permeability was associated with evidence of TJ abnormalities. However, there is limited information on the serological measurement of ZO-1 and its relation to other tests of barrier function in healthy subjects. We investigated the correlation of serum ZO-1, with physiologic measures of intestinal permeability (as the ratio of the fractional excretion of lactulose-mannitol or LMR) in a cohort of 39 healthy FDRs of Crohn's disease (CD) patients. No significant correlation was found between LMR and ZO-1 levels (r2 = 0.004, P < 0.71), or intestinal fatty acid binding proteins (I-FABP) (r2 = 0.004, P < 0.71). In conclusion, our data show that ZO-1 and I-FABP are not a marker of gut permeability as defined by LMR.

AB - Intestinal epithelial cell tight junctions (TJs) contribute to the integrity of the intestinal barrier allowing for control of the physical barrier between external antigens or bacterial products and the internal environment. Zonula occludens-1 (ZO-1) is a protein that modulates intestinal TJs, and serum levels of ZO-1 has been suggested as a biomarker of disrupted barrier function in humans. Previous studies suggested that increased intestinal permeability was associated with evidence of TJ abnormalities. However, there is limited information on the serological measurement of ZO-1 and its relation to other tests of barrier function in healthy subjects. We investigated the correlation of serum ZO-1, with physiologic measures of intestinal permeability (as the ratio of the fractional excretion of lactulose-mannitol or LMR) in a cohort of 39 healthy FDRs of Crohn's disease (CD) patients. No significant correlation was found between LMR and ZO-1 levels (r2 = 0.004, P < 0.71), or intestinal fatty acid binding proteins (I-FABP) (r2 = 0.004, P < 0.71). In conclusion, our data show that ZO-1 and I-FABP are not a marker of gut permeability as defined by LMR.

UR - http://www.scopus.com/inward/record.url?scp=85103876558&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85103876558&partnerID=8YFLogxK

U2 - 10.3389/fphys.2021.645303

DO - 10.3389/fphys.2021.645303

M3 - Article

C2 - 33841181

AN - SCOPUS:85103876558

SN - 1664-042X

VL - 12

JO - Frontiers in Physiology

JF - Frontiers in Physiology

M1 - 645303

ER -

Serum Zonulin Measured by Commercial Kit Fails to Correlate With Physiologic Measures of Altered Gut Permeability in First Degree Relatives of Crohn's Disease Patients

Résumé

Note bibliographique

ASJC Scopus Subject Areas

PubMed: MeSH publication types

Accès au document

Autres fichiers et liens

Empreinte numérique

Citer